Guy Who Told Valeant To Take A Long Walk Off A Short Pier Now Loving The Stock

Andrew Left sees a buying opportunity.
Author:
Updated:
Original:

Now that the the company has dropped 90%, the owner of Citron Research likes what he sees.

Andrew Left, the short seller whose report on Valeant Pharmaceuticals International Inc. triggered the drugmaker’s tailspin, is a buyer of the stock now that many funds are exiting. “I’m long for a trade,” Left said by telephone, confirming comments he made earlier to the TheStreet.com. “Valeant is priced right now like it’s over.” [...] Left, the owner of Citron Research, published a report in October that said Valeant had an Enron-like strategy of recording fake sales using an affiliated pharmacy. While the drugmaker denied the allegations, it severed its relationship with the pharmacy and faced months of turmoil amid scrutiny on its accounting and drug pricing. They culminated in former CEO Mike Pearson’s departure last month.

Short Seller Andrew Left Says Valeant’s a Buy as Big Funds Exit [Bloomberg]

Related

trump-citron

Citron's New Short Strategy: Chumming For Trump

Andrew Left is flinging a whole lot of red meat at the president.

wy-edqo5

With One Fell Tweet, Citron Cleaves Express Scripts Stock Asunder

Lo, pity on the ESRX longs, and glory to the House of Left.

Approx. size of the new pad.

Don't Drop Your Rating On Cathay Pacific While Drinking Your Juice In Hong Kong

Valeant Slayer’s Andrew Left should have kept his thoughts on Cathay Pacific to himself.

trump-citron

Citron Research Bought A Lemon

Andrew Left can’t say that Carson Block didn’t warn him.

Tesla Bubble

Elon Musk Converts An Enemy Into An Apostle

Citron's Andy Left is all "WTF? I love Tesla now!"